1 Mar 2019 08:43Last reply 1 Mar 2019 18:15
I just had a quick read through of it.
To be honest I've met better second hand car salesman.
I'm dyslexic but he manages make me look good!
@mmhhpp - Please do not take this as a personal criticism
This is an excellent example of crap that floats around on the Internet, but looks legit.
1 - it is a 'report' generated by a company whose entire business model is in selling reports of highly questionable quality to wannabe investors.
2 - no decent brokerage/fund worth its salt buys this sort of thing, they have in-house expertise.
3 - there is zero medical input. It was compiled by a researcher whose biggest boast in his bio is that he 'worked as a research analyst with a big equity company'. Really, a big name would be mentioned. It is like saying you went to a University near to Harvard. Prob a community college.
4 - it is taking an exclusively financial opportunity view. Usually looking to recommend undervalued shares to buy early (heaven forbid the small firms ever tried to influence these reports, only a cynic would suggest that) as investing in parma research is a very risky field, fraught with danger. Promising companies can often go pop overnight if a drug fails at any stage in trial.
The aim of the company flogging the free sample is only to try and hook you in to buy the whole report and preferably to subscribe to reports. They are quite underhand. request the sample (use a different email) and watch how fast they are all over you trying to sign you up with deals.
They have no value or credibility - despite how they try and sound - regarding a medical/patient type of view.
I'd hazard a guess that they rehashed much of the MS-SMART trial output - read here http://www.ms-smart.org/ or go to http://solo.bodleian.ox.ac.uk/primo-explore/fulldisplay?docid=TN_whiterose134134&context=PC&vid=SOLO&lang=en_US&search_scope=LSCOP_ALL&adaptor=primo_central_multiple_fe&tab=local&query=any,contains,SPMS%20drugs&sortby=rank&offset=0 for the abstract unless you have academic library access.
This is all about interrogating the source of the information, understanding their agenda and motivations as well as all about and CoI - conflicts of interest - they may have!
I have written about this here: https://theproblemwithdata.com/2018/12/10/how-do-i-know/ Skip to Section 2
@dominics 👏 I was going to say bumph but craps way better!
@mmhhpp , the only point that you’re missing is that the future isn’t here yet!
A long time ago, I got advised that if someone was writing a report regarding the future, then, if they really knew the future, they’d be sitting at home making money, rather than speculating and writing reports………. 😕
I agree entirely with you all!
I get so furious about this type of news ....,😡
I must be a dumbwit, but I don’t understand the phrase ‘ Progressive RRMS’, given that MS is a by default Progressive condiction?
@vixen , it is a bit of a silly expression. Perhaps we can transition to non-remitting MS? 🤣
Donald Trump has a name for this stuff "fake news!" I honestly would never have thought I'd ever agree with him!
Snake oil will come next, you watch.
It is MS plain and simple. RRMS,SPMS and PPMS are different levels of the disease. Most are dxed as RRMS and then advance to SPMS over time. It seems that the MS attacks get more spread out over time and we don’t notice things as much. Yearly visits to nuero May show progression or possibly plateauing of activity. There is no cure. Lucky to be on plateau. Things continue to progress without us knowing. We as patients just have to roll with it. Siponomod is near approval for SPMS patients. It was tested in trials on SPMS patients. It is an oral drug.
Charity Number: 1117194 (England and Wales)
Registered company: 06000961
© 2020 Shift.ms
Registered address:Shift.ms, Platform, New Station Street, LS1 4JBLondon office:Shift.ms, Somerset House, Strand, West Goods Entrance, London WC2R 1LA